Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib and Venetoclax in IDH2-Mutated Myeloid Malignancies
NCT04092179Phase 2Terminated
- Sponsor
- University Health Network
- Start
- Nov 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enasidenib, venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), sponsored by University Health Network. Started Nov 2020; status: terminated.
02
Drugs
enasidenibvenetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT04092179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092179.